Hematology Service. Hematologic Cancer Group, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Osakidetza, Plaza Cruces s/n, Barakaldo, Spain; Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Medicine and Nursing and Faculty of Science and Technology, University of the Basque Country, UPV/EHU, Barrio Sarriena s/n, 48940, Leioa, Spain.
Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Medicine and Nursing and Faculty of Science and Technology, University of the Basque Country, UPV/EHU, Barrio Sarriena s/n, 48940, Leioa, Spain; Medical Oncology Service, Basurto University Hospital, Avenida de Montevideo, 18, 48013, Bilbao, Spain.
Crit Rev Oncol Hematol. 2021 Mar;159:103247. doi: 10.1016/j.critrevonc.2021.103247. Epub 2021 Jan 27.
Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma and usually presents as an indolent disease. However, some patients present poor outcomes, and FL can transform into more aggressive lymphomas, such as Diffuse Large B cell lymphoma (DLBCL). MicroRNAs (miRNA) are small RNA molecules that participate in posttranscriptional regulation of gene expression, that are emerging biomarkers in cancer. In this systematic review, we included studies evaluating miRNA expression in tumor tissue as diagnosis, transformation or prognosis biomarkers in FL. We identified several miRNAs, which could be diagnostic biomarkers in FL: miR-155-5p and miR-9-3p as miRNAs of potential utility for diagnosis of FL, and miR-150 and miR-17-92 cluster for differential diagnosis between FL and DLBCL. Prognosis and transformation prediction have not been studied in enough depth to draw solid conclusions. Further research is needed to exploit the potential of this field.
滤泡性淋巴瘤（FL）是第二常见的非霍奇金淋巴瘤，通常表现为惰性疾病。然而，一些患者预后不良，FL 可转化为侵袭性更强的淋巴瘤，如弥漫性大 B 细胞淋巴瘤（DLBCL）。微小 RNA（miRNA）是参与基因表达转录后调控的小 RNA 分子，是癌症中新兴的生物标志物。在本系统评价中，我们纳入了评估肿瘤组织中 miRNA 表达作为 FL 诊断、转化或预后生物标志物的研究。我们确定了几种 miRNA，它们可能是 FL 的诊断生物标志物：miR-155-5p 和 miR-9-3p 作为 FL 潜在有用的诊断 miRNA，miR-150 和 miR-17-92 簇用于 FL 和 DLBCL 的鉴别诊断。预后和转化预测尚未进行足够深入的研究，无法得出确凿的结论。需要进一步研究以挖掘该领域的潜力。
